OrbiMed’s DexCom DXCM Stock Holding History

OrbiMed’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-50,000	Closed	-$4.67M	–	120
2023 Q3	$4.67M	Buy	+50,000	New	+$5.64M	0.1%	101

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OrbiMed's DXCM Position: Q3 2024 in Review

OrbiMed sold out of DexCom (DXCM) in Q3 2024, closing a stake of 289,900 shares — an estimated $32.9M sold.

OrbiMed first reported a position in DXCM in Q4 2018 and held it in 17 quarters. The position peaked at $127M in Q2 2021. 890 funds tracked by Wall St. Rank hold DXCM as of Q3 2024.

OrbiMed reported no remaining DexCom position as of Q3 2024 after selling out during the quarter.
OrbiMed sold 289,900 DexCom shares in Q3 2024, an estimated $32.9M.
OrbiMed first reported a position in DexCom in Q4 2018 and held it in 17 quarters.
OrbiMed's DexCom position peaked at $127M in Q2 2021.
890 funds tracked by Wall St. Rank held DexCom as of Q3 2024.

Based on OrbiMed's 13F filing for Q3 2024, filed 14 Nov 2024.